Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamaoncol.2018.1712 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case of Radiation-Induced Angiosarcoma after Breast-Conserving Surgery with Hypofractionated Radiotherapy in a Japanese Patient.
Acta Med Okayama
December 2024
Department of Radiology, Kawasaki Medical School.
Radiation-induced angiosarcoma (RIAS) is a rare, late adverse event of radiotherapy comprising approximately half of all radiation-induced sarcomas. It has a relatively short latency period and generally unfavorable prognosis. This study presents a case of RIAS that developed 5 years and 11 months after the completion of hypofractionated radiotherapy (42.
View Article and Find Full Text PDFPrimary Pulmonary Angiosarcoma Found Incidentally in a Complicated Patient: A Rare Case Report.
Clin Respir J
August 2024
Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Introduction: Primary pulmonary angiosarcoma (PPA) is a highly aggressive and rare malignancy originating from the endothelial cells of blood vessels in the lungs. PPA is an extremely rare subtype, with less than 30 cases reported to date. PPA is not only challenging to diagnose but also has a poor prognosis, often resulting in a high mortality rate within a year of diagnosis, regardless of the treatment approach.
View Article and Find Full Text PDFBiomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel.
Urol Oncol
November 2024
Department of Genitourinary Oncology, Barts Cancer Institute, QMUL, London, UK.
Article Synopsis
- Taxane-based chemotherapy, specifically paclitaxel, is commonly used for treating platinum- and immunotherapy refractory metastatic urothelial carcinoma (mUC), but survival outcomes are generally poor and biomarkers for predicting outcomes are lacking.
- A study was conducted using whole-transcriptome profiles from patients enrolled in a trial (PLUTO) to evaluate gene signatures related to survival, focusing on factors like immuno-oncology, angiogenesis, and genome instability.
- Results indicated that patients with high expressions of genome instability and evading growth suppressors experienced significantly better progression-free survival (PFS) and overall survival (OS), while activation of angiogenesis was associated with worse outcomes across both treatment cohorts.
Elucidating the role of Pyroptosis in papillary thyroid cancer: prognostic, immunological, and therapeutic perspectives.
Cancer Cell Int
January 2024
Division of Thyroid Surgery, The China-Japan Union Hospital of Jilin University, Jilin Provincial Key Laboratory of Surgical Translational Medicine, Jilin Provincial Precision Medicine Laboratory of Molecular Biology and Translational Medicine on Differentiated Thyroid Carcinoma, Changchun, 130031, Jilin, China.
Background: Pyroptosis, an inflammatory form of programmed cell death, has been implicated in the pathogenesis and progression of several cancers. However, the significance of pyroptosis-related genes (PRGs) in papillary thyroid cancer (PTC) remains unclear.
Methods: Transcriptome and clinical data of PTC patients were obtained from The Cancer Genome Atlas.
Pharmacovigilance Study of Anticancer Drugs in a Tertiary Care Teaching Hospital in North India: A Retrospective Study.
Cureus
September 2023
Oncology, Guru Gobind Singh Medical College and Hospital, Baba Farid University of Health Sciences, Faridkot, IND.
Introduction: Anticancer agents are responsible for a majority of adverse drug reactions (ADRs) in cancer patients. ADR reporting with anticancer drugs is very rare in India due to the lack of awareness and knowledge about the Pharmacovigilance Programme of India. Hence, this study was done to assess the pattern of ADRs with anticancer agents in cancer patients and to increase awareness about ADR monitoring among healthcare professionals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!